Search

Your search keyword '"Scheltens, Philip"' showing total 7,007 results

Search Constraints

Start Over You searched for: Author "Scheltens, Philip" Remove constraint Author: "Scheltens, Philip"
7,007 results on '"Scheltens, Philip"'

Search Results

1. Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study

2. Revised criteria for the diagnosis and staging of Alzheimer’s disease

7. Biomarker-based staging of Alzheimer disease: rationale and clinical applications

8. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease

9. Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study

10. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

16. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

18. Radiologie van hoofd en hersenen

19. Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease

21. Dutch Brain Research Registry for study participant recruitment: Design and first results

23. Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum

24. Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease

25. Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

26. The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in 8 countries

28. Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood

30. Latent atrophy factors related to phenotypical variants of posterior cortical atrophy.

31. World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia.

32. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

33. The “rights” of precision drug development for Alzheimer’s disease

34. Quantification supports amyloid-PET visual assessment of challenging cases: results from the AMYPAD-DPMS study

36. White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study

37. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

38. Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia

40. New insights into the genetic etiology of Alzheimer’s disease and related dementias

41. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

42. The natural history of primary progressive aphasia: beyond aphasia

44. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

47. Rationale and design of the “NEurodegeneration: Traumatic brain injury as Origin of the Neuropathology (NEwTON)” study: a prospective cohort study of individuals at risk for chronic traumatic encephalopathy

48. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

49. Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

Catalog

Books, media, physical & digital resources